Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 08:40PM GMT
Release Date Price: $58.57 (+0.15%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ionis with us. And we have Brett Monia, the CEO of the company. So Brett, thanks for being here.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And maybe to start here at a high level, could you walk us through your key programs, the outlook for the remainder of 2020 and your strategy here on the [forward]?

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Sure. Thank you, Salveen, and it's a pleasure to be here today. So yes, I'd love to give an update on -- at a high level on where the company is today on the key programs.

So starting with SPINRAZA. Of course, SPINRAZA continues to perform as it should, as a blockbuster medicine as it should. We're now approaching nearly 11,000 patients globally that are on SPINRAZA. It is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot